Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Response by Björnsson et al to Letter Regarding Article, “Large-Scale Screening for Monogenic and Clinically Defined Familial Hypercholesterolemia in Iceland”

Response by Björnsson et al to Letter Regarding Article, “Large-Scale Screening for Monogenic and... Arteriosclerosis, Thrombosis, and Vascular Biology LETTER TO THE EDITOR Response by Björnsson et al to Letter Regarding Article, “Large-Scale Screening for Monogenic and Clinically Defined Familial Hypercholesterolemia in Iceland” Eythór Björnsson, Gudmundur Thorgeirsson, Anna Helgadóttir, Daníel F. Gudbjartsson, Hilma Hólm, Unnur Thorsteinsdóttir, Patrick Sulem, Kári Stefánsson In Response: measurements in our sample, we found extremely high We thank Tromp et al for their interest in our article. molar concentration of lipoprotein(a) (>200 nmol/L) in As the authors mention, we found that the clinical familial 9.3% (n=58 out of 622) of individuals with clinical FH, hypercholesterolemia (FH) phenotype (defined as prob- compared with 4.4% (n=1683 out of 38 426) of those able or definite FH using modified Dutch lipid clinic net- without clinical FH. Thus, it is reasonable to assume that work criteria) was explained by monogenic FH in only about 9% of clinical FH in our study may be explained, about 5% of cases. Tromp et al wonder whether this find- at least in part, by extremely high levels of lipoprotein(a). ing may be related to overestimation of the prevalence Importantly, the cardiovascular risk of these individuals of clinical FH in our study due to: (1) the use of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Arteriosclerosis Thrombosis and Vascular Biology Wolters Kluwer Health

Response by Björnsson et al to Letter Regarding Article, “Large-Scale Screening for Monogenic and Clinically Defined Familial Hypercholesterolemia in Iceland”

Loading next page...
 
/lp/wolters-kluwer-health/response-by-bj-rnsson-et-al-to-letter-regarding-article-large-scale-VvaOzNvH0J

References (6)

Publisher
Wolters Kluwer Health
Copyright
© 2021 American Heart Association, Inc.
ISSN
1079-5642
eISSN
1524-4636
DOI
10.1161/atvbaha.121.317201
Publisher site
See Article on Publisher Site

Abstract

Arteriosclerosis, Thrombosis, and Vascular Biology LETTER TO THE EDITOR Response by Björnsson et al to Letter Regarding Article, “Large-Scale Screening for Monogenic and Clinically Defined Familial Hypercholesterolemia in Iceland” Eythór Björnsson, Gudmundur Thorgeirsson, Anna Helgadóttir, Daníel F. Gudbjartsson, Hilma Hólm, Unnur Thorsteinsdóttir, Patrick Sulem, Kári Stefánsson In Response: measurements in our sample, we found extremely high We thank Tromp et al for their interest in our article. molar concentration of lipoprotein(a) (>200 nmol/L) in As the authors mention, we found that the clinical familial 9.3% (n=58 out of 622) of individuals with clinical FH, hypercholesterolemia (FH) phenotype (defined as prob- compared with 4.4% (n=1683 out of 38 426) of those able or definite FH using modified Dutch lipid clinic net- without clinical FH. Thus, it is reasonable to assume that work criteria) was explained by monogenic FH in only about 9% of clinical FH in our study may be explained, about 5% of cases. Tromp et al wonder whether this find- at least in part, by extremely high levels of lipoprotein(a). ing may be related to overestimation of the prevalence Importantly, the cardiovascular risk of these individuals of clinical FH in our study due to: (1) the use of

Journal

Arteriosclerosis Thrombosis and Vascular BiologyWolters Kluwer Health

Published: Jan 23, 2022

There are no references for this article.